Which people should get GamaSTAN (IG) for prevention of hepatitis A?

Please see details of the recommendations for the use of IG for the prevention of hepatitis A provided in Table 4 (page 19) and Appendices A and B of the 2020 ACIP recommendations for the prevention of hepatitis A infection: www.cdc.gov/mmwr/volumes/69/rr/pdfs/rr6905a1-H.pdf.

Below is a brief summary of the recommendations:

Preexposure prophylaxis with IG for travel to areas of intermediate or high hepatitis A endemicity:

• Infants younger than age 6 months and other travelers for whom HepA vaccine is declined or contraindicated
• Previously unvaccinated people with chronic liver disease vaccinated within 2 weeks of departure may consider IG in addition to vaccination, based upon the clinician’s risk assessment
• Previously unvaccinated people who are immunocompromised may consider IG in addition to vaccination, regardless of the timing of vaccination, based upon the clinician’s risk assessment
• Previously unvaccinated people who are over age 40 years and vaccinated within 2 weeks of departure may consider IG in addition to vaccination, based upon the clinician’s risk assessment

Postexposure prophylaxis with IG within 2 weeks after exposure to hepatitis A virus (HAV):

• Infants under age 12 months
• Previously unvaccinated immunocompromised adults (including HIV+), in addition to vaccination
• Previously unvaccinated adults with chronic liver disease, in addition to vaccination
• Previously unvaccinated adults over age 40 years, consider IG in addition to vaccination, based upon clinician risk assessment
• People with HIV infection, previously vaccinated, consider IG following a high-risk exposure (household or sexual contact), based upon clinician risk assessment